

Supplementary material:

Title.

Efficacy and Safety of Restrictive versus Liberal Blood Transfusion Strategies for Acute Myocardial Infarction and Anemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Running Title.

Restrictive versus liberal blood transfusion for myocardial infarction and anemia.

Authors.

Ahmed Mazen Amin¹, Karim Ali², Hossam Elbenawi¹, Alhassan Saber³, Mohamed Abuelazm⁴, Basel Abdelazeem⁵.

Affiliations.

1. Faculty of Medicine, Mansoura University, Mansoura, Egypt.
2. Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA
3. Faculty of Medicine, Minia University, Minya, Egypt.
4. Faculty of Medicine, Tanta University, Tanta, Egypt.
5. Department of Cardiology, West Virginia University, West Virginia, USA.

Keywords.

Blood transfusion, Liberal, Restrictive, Myocardial infarction, Acute coronary syndrome, Anemia.

Contents:**Figure.**

Figure S1: Forest plot of hemoglobin change, transfusion outcomes, and transfusion-related adverse events.

Figure S2: Trial sequential analysis of hemoglobin level change.

Tables.

Table S1: Search strategy.

Table S2: Summary characteristics (Restrictive and liberal blood transfusion strategy description and the inclusion criteria).

Table S3: Baseline characteristics (Killip class and patients comorbidities).

Table S4: Description of risk of bias (ROB) assessment.

Table S5: Sensitivity analysis.





(A) Hemoglobin level (g/dl) Change**(B) Units of blood transfused per patient****(C) Units of blood transfused****(D) Blood transfusion related adverse events at 30 days**

Figure S1: Forest plot of hemoglobin change, transfusion outcomes, and transfusion-related adverse events.

RIS is a Two-sided graph




Figure S2: Trial sequential analysis of hemoglobin level change.

| Database | Search Terms | Search Field | Search Results |
|----------|---|---------------------------|----------------|
| Pubmed | ("Liberal transfusion" OR "Restrictive transfusion" OR "Restrictive blood transfusion" OR "liberal blood transfusion") AND ("Myocardial infarct*" OR "Coronary artery disease" OR Angina OR "acute coronary syndrome" OR "cardiovascular stroke" OR "heart attack*" OR MI) AND anemi* | All Field | 60 |
| Cochrane | ("Liberal transfusion" OR "Restrictive transfusion" OR "Restrictive blood transfusion" OR "liberal blood transfusion") AND ("Myocardial infarct*" OR "Coronary artery disease" OR Angina OR "acute coronary syndrome" OR "cardiovascular stroke" OR "heart attack*" OR MI) AND anemi* | All Field | 35 |
| WOS | ("Liberal transfusion" OR "Restrictive transfusion" OR "Restrictive blood transfusion" OR "liberal blood transfusion") AND ("Myocardial infarct*" OR "Coronary artery disease" OR Angina OR "acute coronary syndrome" OR "cardiovascular stroke" OR "heart attack*" OR MI) AND anemi* | All Field | 83 |
| SCOPUS | TITLE-ABS-KEY (("Liberal transfusion" OR "Restrictive transfusion" OR "Restrictive blood transfusion" OR "liberal blood transfusion") AND ("Myocardial infarct*" OR "Coronary artery disease" OR angina OR "acute coronary syndrome" OR "cardiovascular stroke" OR "heart attack*" OR mi) AND anemi*) | Title, Abstract, Keywords | 84 |

| | | | |
|--------|---|-----------|----|
| EMBASE | <p>#4. #1 AND #2 AND #3 29</p> <p>#3. anemia:ti,ab,kw 221,554</p> <p>#2. 'heart infarction':ti,ab,kw OR 'coronary artery disease':ti,ab,kw OR 'angina pectoris':ti,ab,kw OR 'acute coronary syndrome':ti,ab,kw OR 'cardiovascular stroke':ti,ab,kw OR mi:ti,ab,kw 341,000</p> <p>#1. 'liberal transfusion':ti,ab,kw OR 'restrictive transfusion':ti,ab,kw OR 'restrictive blood transfusion':ti,ab,kw OR 'liberal blood transfusion':ti,ab,kw 1,444</p> | All Field | 29 |
|--------|---|-----------|----|

Table S1: Search Strategy.

| Study ID | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Main Inclusion Criteria |
|---|---|---|---|
| Carson et al. 2013 | Patients were permitted to receive blood for symptoms from anemia or for a hemoglobin < 8 g/dL. | Patients received one or more units of blood to raise the hemoglobin level ≥ 10 g/dL. | 1) greater than 18 years of age; 2) had either a) ST segment elevation myocardial infarction, b) Non ST segment elevation myocardial infarction, c) unstable angina, or d) stable coronary artery disease undergoing a cardiac catheterization; and 3) had a hemoglobin concentration less than 10 g/dL at the time of random allocation. |
| Carson et al. 2023 (MINT) | Transfusion was permitted but not required when the hemoglobin level was less than 8 g per deciliter and was strongly recommended when the level was less than 7 g per deciliter or when anginal symptoms were not controlled with medications | One unit of packed red cells was administered after randomization and red cells were transfused to maintain the hemoglobin level at or above 10 g per deciliter until the time of hospital discharge or 30 days | Adults (≥ 18 years of age) with ST-segment elevation or non-ST-segment elevation myocardial infarction, defined in accordance with the Third Universal Definition of Myocardial Infarction, along with anemia (hemoglobin level, <10 g per deciliter within 24 hours before randomization). |
| Cooper et al. 2011 (The CRIT) | RBC transfusion when their hematocrit decreased 24% with the goal of maintaining a hematocrit from 24% to 27%. | RBC transfusion when their hematocrit decreased 30% with the goal of maintaining a hematocrit from 30% to 33%. | Patients in whom the hematocrit was 30% within 72 hours of symptom onset with AMI |
| Ducrocq et al. 2021, Gonzalez-Juanatey et al. 2022 (The REALITY) | No transfusion was to be performed unless hemoglobin level decreased to less than or equal to 8 g/dL, with a target range for posttransfusion hemoglobin of 8 to 10 g/dL (the initial protocol used a threshold of 7 g/dL but this was changed to 8 g/dL to maximize investigator adherence to the protocol before inclusion of the first patient). | Transfusion was to be performed after randomization on all patients with a hemoglobin level less than or equal to 10 g/dL, with a target posttransfusion hemoglobin level of at least 11g/dL. | Patients had to be aged at least 18 years and have AMI (with or without ST-segment elevation with a combination of ischemic symptoms occurring in the 48 hours before admission and elevation of biomarkers of myocardial injury) and a hemoglobin level between 7 and 10 g/dL. |

Table S2: Summary characteristics (Restrictive and liberal blood transfusion strategy description and the inclusion criteria).

AMI: Acute myocardial infarction.

| Study ID | Killip Class N. (%) | | | | | | | | Comorbidities N.(%) | | | | | | | | | | | | | | | |
|--|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|--|------------------------------------|
| | 1 | | 2 | | 3 | | 4 | | Prior myocardial infarction | | Percutaneous coronary intervention | | Coronary artery bypass graft | | Congestive heart failure | | Hypertension | | Dislipidemia | | Diabetes mellitus | | Bleeding | |
| | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy | Restrictive blood transfusion strategy | Liberal blood transfusion strategy |
| Carson et al. 2013 | NA | NA | NA | NA | NA | NA | NA | NA | 17 (30.9) | 13 (23.6) | 22 (40) | 24 (43.6) | 18 (32.7) | 16 (29.1) | 13 (23.6) | 12 (21.8) | 45 (81.8) | 47 (85.5) | 36 (65.5) | 38 (69.1) | 29 (52.7) | 34 (61.8) | 9 (16.4) | 6 (10.9) |
| Carson et al. 2023 (MINT) | NA | NA | NA | NA | NA | NA | NA | NA | 589 (33.7) | 549 (31.3) | 623 (35.6) | 577 (32.9) | 372 (21.3) | 390 (22.2) | NA | NA | NA | NA | NA | NA | 948(5 4.2) | 948(5 4) | 246 (14.1) | 213 (12.1) |
| Cooper et al. 2011 (The CRIT) | 16(67) | 11(52) | 2(8) | 5(24) | 3(13) | 0 | 3(13) | 5(25) | NA | NA | 6(25) | 5(24) | 4(17) | 6(29) | NA | NA | 18(75) | 19(91) | 15(63) | 16(76) | 13(54) | 17(81) | NA | NA |
| Ducrocq et al. 2021, Gonzalez-Juanatey et al. 2022 (The REALITY) | 189 (56.3) | 183 (57.0) | 87 (25.9) | 88 (27.4) | 54 (16.1) | 39 (12.1) | 6 (1.8) | 11 (3.4) | 121 (35.4) | 119 (36.7) | 114 (33.3) | 111 (34.3) | 44 (12.9) | 42 (13.0) | 44 (12.9) | 38 (11.7) | 272 (79.5) | 256 (79.0) | 189 (55.3) | 201 (62.0) | 176 (51.5) | 158 (48.8) | 36 (10.5) | 49 (15.1) |

Table S3: Baseline characteristics (Killip class and patients comorbidities).

NA: not available

| Study ID | Domain | Decision | Description |
|--|--|------------------------|---|
| Carson et al. 2013 | Randomization process | Low risk | Treatment group randomization was done by using an automated telephone system. They were unable to blind the treating physician or patient to the transfusion strategy, and there were no apparent differences between the two groups. |
| | Deviations from intended interventions | Low risk | They were unable to blind the treating physician or patient to the transfusion strategy. There was no deviation from the intended interventions because of the trial context. Additionally, the analysis was done by the intention to treat analysis. |
| | Missing outcome data | Low risk | Outcome data of nearly all randomized patients were available. |
| | Measurement of the outcome | Low risk | Appropriate tools were used to measure the outcome without difference between the two group arms. |
| | Selection of the reported result | Low risk | All outcomes, measurement tools, and analysis plans were pre-specified in the study protocol. |
| | <u>OVERALL</u> | <u>LOW RISK</u> | |
| Carson et al. 2023 (MINT) | Randomization process | Low risk | The patients were randomly assigned in a 1:1 ratio to a restrictive or liberal transfusion strategy by means of a Web-based system and there were no apparent differences between the two groups. |
| | Deviations from intended interventions | Low risk | This study was an open-label study. There was no deviation from the intended interventions because of the trial context. Additionally, the analysis was done by the intention to treat analysis. |
| | Missing outcome data | Low risk | Outcome data were available for nearly all participants. |
| | Measurement of the outcome | Low risk | Appropriate tools were used to measure the outcome without difference between the two group arms. |
| | Selection of the reported result | Low risk | No information about whether the outcomes and the analysis methods were pre-specified. |
| | <u>OVERALL</u> | <u>LOW RISK</u> | |
| Cooper et al. 2011 (The CRIT) | Randomization process | Low risk | This study was open-label, and the patients were randomly assigned in a 1:1 ratio to 1 of 2 treatment groups by the coordinating center using consecutively numbered opaque envelopes and there were no apparent differences between the two groups. |
| | Deviations from intended interventions | Low risk | This study was an open-label study. There was no deviation from the intended interventions because of the trial context. Additionally, the analysis was done by the intention to treat analysis. |
| | Missing outcome data | Low risk | Outcome data were available for nearly all participants. |
| | Measurement of the outcome | Low risk | Appropriate tools were used to measure the outcome without difference between the two group arms. |
| | Selection of the reported result | Low risk | data that produced this result analysed in accordance with a pre-specified analysis plan. |
| | <u>OVERALL</u> | <u>LOW RISK</u> | |
| Ducrocq et al. 2021, Gonzalez-Juanatey et al. 2022 | Randomization process | Low risk | A web-based randomization system was used for the randomization process and there were no apparent differences between the two groups. |
| | Deviations from intended interventions | Low risk | This study was an open-label study. There was no deviation from the intended interventions because of the trial context. Additionally, the analysis was done by the intention to treat analysis. |
| | Missing outcome data | Low risk | Outcome data were available for nearly all participants. |

| | | | |
|----------------------|----------------------------------|------------------------|---|
| (The REALITY) | Measurement of the outcome | Low risk | Appropriate tools were used to measure the outcome without difference between the two group arms. |
| | Selection of the reported result | Low risk | data that produced this result analysed in accordance with a pre-specified analysis plan. |
| | <u>OVERALL</u> | <u>LOW RISK</u> | |

Table S4: Description of risk of bias (ROB) assessment.

| Outcome | No. of Participants (/) | No. of trials | Quantitative data synthesis | | | | Heterogeneity analysis | | |
|---|-------------------------|---------------|-----------------------------|-----------------|---------|----------|------------------------|---------|--------------------|
| | | | MD | 95% CI | Z value | p-value | df | p-value | I ² (%) |
| MACE at 30 days. | | | | | | | | | |
| Carson et al. 2013 | 2115/2100 | 3 | 0.77 | [0.46, 1.29] | 0.98 | 0.33 | 2 | 0.007 | 80% |
| Carson et al. 2023 (MINT) | 420/400 | 3 | 0.84 | [0.34, 2.08] | 0.37 | 0.71 | 2 | 0.007 | 80% |
| Cooper et al. 2011 (The CRIT) | 2145/2134 | 3 | 1.11 | [0.75, 1.64] | 0.51 | 0.61 | 2 | 0.05 | 66% |
| Ducrocq et al. 2021 (The REALITY) | 1827/1831 | 3 | 0.98 | [0.42, 2.25] | 0.05 | 0.96 | 2 | 0.005 | 81% |
| Cardiac death at 30 days. | | | | | | | | | |
| Carson et al. 2013 | 2091/2079 | 2 | 1.05 | [0.36, 3.04] | 0.10 | 0.92 | 1 | 0.004 | 88% |
| Carson et al. 2023 (MINT) | 396/379 | 2 | 1.69 | [0.14, 20.08] | 0.68 | 0.42 | 1 | 0.02 | 81% |
| Ducrocq et al. 2021 (The REALITY) | 1803/1810 | 2 | 2.41 | [0.75, 7.77] | 1.47 | 0.14 | 1 | 0.18 | 44% |
| New or exacerbating heart failure at 30 days. | | | | | | | | | |
| Carson et al. 2013 | 2115/2100 | 3 | 0.76 | [0.43, 1.33] | 0.97 | 0.33 | 2 | 0.15 | 47% |
| Carson et al. 2023 (MINT) | 420/400 | 3 | 0.86 | [0.23, 3.22] | 0.22 | 0.82 | 2 | 0.03 | 71% |
| Cooper et al. 2011 (The CRIT) | 2145/2134 | 3 | 1.02 | [0.63, 1.65] | 0.09 | 0.93 | 2 | 0.22 | 33% |
| Ducrocq et al. 2021 (The REALITY) | 1827/1831 | 3 | 0.88 | [0.28, 2.80] | 0.21 | 0.83 | 2 | 0.03 | 71% |
| Hemoglobin level (g/dl) Change. | | | | | | | | | |
| Carson et al. 2013 | 2091/2079 | 2 | -1.47 | [-1.76, -1.18] | 9.87 | <0.00001 | 1 | 0.01 | 84% |
| Carson et al. 2023 (MINT) | 396/379 | 2 | -1.30 | [-1.49, -1.11] | 13.31 | <0.00001 | 1 | 0.96 | 0% |
| Ducrocq et al. 2021 (The REALITY) | 1803/1810 | 2 | -1.52 | [-1.77, -1.26] | 11.50 | <0.00001 | 1 | 0.14 | 54% |
| Units of blood transfused per patient. | | | | | | | | | |
| Carson et al. 2013 | 2091/2079 | 2 | -0.87 | [-2.73, 1.00] | 0.91 | 0.36 | 1 | 0.00001 | 98% |
| Carson et al. 2023 (MINT) | 397/379 | 2 | -0.50 | [-1.67, 0.66] | 0.85 | 0.40 | 1 | 0.0002 | 93% |
| Ducrocq et al. 2021 (The REALITY) | 1804/1810 | 2 | -1.47 | [-2.17, -0.78] | 4.16 | <0.0001 | 1 | 0.001 | 91% |
| Number of patients who transfused zero units of red blood cells. | | | | | | | | | |
| Carson et al. 2013 | 2091/2079 | 2 | 44.99 | [2.35, 861.22] | 2.53 | 0.01 | 1 | 0.003 | 89% |
| Carson et al. 2023 (MINT) | 397/379 | 2 | 48.72 | [1.69, 1402.96] | 2.27 | 0.02 | 1 | 0.003 | 89% |

| | | | | | | | | | |
|--|-----------|---|-------|----------------|-------|----------|---|-------|-----|
| Ducrocq et al. 2021 (The REALITY) | 1804/1810 | 2 | 13.09 | [10.70, 16.01] | 24.98 | <0.00001 | 1 | 0.97 | 0% |
| Number of patients who transfused one unit of red blood cells. | | | | | | | | | |
| Carson et al. 2013 | 2091/2079 | 2 | 0.60 | [0.53, 0.67] | 8.64 | <0.00001 | 1 | 0.73 | 0% |
| Carson et al. 2023 (MINT) | 397/379 | 2 | 0.40 | [0.20, 0.80] | 2.61 | 0.009 | 1 | 0.08 | 67% |
| Ducrocq 2021, Gonzalez-Juanatey 2022 (The REALITY) | 1804/1810 | 2 | 0.43 | [0.20, 0.92] | 2.16 | 0.03 | 1 | 0.02 | 82% |
| Number of patients who transfused two units of red blood cells. | | | | | | | | | |
| Carson et al. 2013 | 2091/2079 | 2 | 0.36 | [0.22, 0.57] | 4.24 | <0.0001 | 1 | 0.002 | 89% |
| Carson et al. 2023 (MINT) | 397/379 | 2 | 0.45 | [0.35, 0.59] | 6.05 | <0.00001 | 1 | 0.62 | 0% |
| Ducrocq et al. 2021 (The REALITY) | 1804/1810 | 2 | 0.28 | [0.24, 0.34] | 14.77 | <0.00001 | 1 | 0.80 | 0% |

Table S5: Sensitivity analysis

MD: mean difference; CI: confidence interval; df: degrees of freedom.